Bal Pharma Ltd., (BPHL), was originally incorporated as a private limited company on the 19th, May 1987. BPHL, on 22nd Mar 1990, took over a pharmaceutical products manufacturing unit located at 21-22, Bommasandra Industrial area, Bangalore District. The unit was taken over through Karnataka State Finance Corporation, for a consideration of Rs.25.18 lacs. After take over, BPHL, commenced the activity of manufacture of formulations at the above plant from Sep 1991. The constitution of the company, has been converted into a public limited company on 25.7.1994. Fresh certificate of incorporation has been obtained on 9th Aug 1994. The Main objects of the Company set out in the Memorandum of Association of the Company are: 1. To Carry on the business of analytical chemists, druggists, drysalters and manufacturers, importers, repackers of and dealers in pharmaceutical, medicinal, chemical, biological, and biochemical and electrolytic drugs, chemicals, ingredients, products and compounds. 2. To manufacture, prepare, import, export, buy sell, supply, and distribute, store, stock, maintain and otherwise handle. deal in and carry on business of all kinds and varieties of patent medicines, drugs, mixtures, tablets, capsules, pills, powders, pharmaceuticals, chemicals, medicals and medicinal products, preparations and materials, sterilised injections, vaccines, sera, immunogens, phylacogens and surgical dressings. 3. To purchase, produce, manufacture, grow, raise, sell or otherwise handle raw materials of all kinds for manufacture of pharmaceuticals, medicines and drugs. Present business of the company. BPHL, is engaged in the manufacture of Pharmaceutical formulations viz Paracetamol, Aluminium Hydroxide, Povidone Iodine, Alprazolam, Gliclazide, Griseofulvin, Lactobacillus, Rifampicin, Piroxicam and Amoxycillin etc. INFRASTRUCTURE AVAILABLE The production facilities for pharmaceutical formulations are set up at 21-22, Bommasandra Industrial area, Bangalore. The factory is located at a distance of 20 KMs from Bangalore. It has facilities for manufacture of tablets, capsules, liquids and ointments. The equipments installed for the manufacture of above products are as under. (a) The tabletting plant is equipped with planetary mixers, tray and fluid bed dryers, rotary compression machines and blister packing machines. (b) The capsule manufacturing plant is equipped with sifters, multimills, blenders, hand filling machines, semi-automatic filling machines and capsule polishing machines. (c) The ointment manufacturing plant is equipped with a planetory mixer and an automatic tube filling machine. (d) The equipments in the oral liquid area include homogenizer, colloidal mill, filter process, rotary bottle washing machine and automatic labelling machine. (e) The plant is equipped with standard measuring devices, air conditioners, The facilities are modern and conform to the latest 'Good manufacturing practices' (GMP). The company holds a valid GMP certificate. The GMP certifies that the company has the required technical personnel, quality management system, premises & equipments, documentation, quality control and inspection facilities for manufacture of quality products as per specifications. The existing infrastructure would enable the company to produce the following products at 100% capacity utilisation. Tablets 250 Million Nos p.a. Capsules 90 Million Nos p.a. Liquids 750 Kilo Litres p.a Ointments 75 Metric Tonnes p.a. The unit is equipped with facilities for quality testing of the company's products. 2001 -Bal Pharma acquires injectibles co in South African 2003 -The company has recommended a dividend of 12% 2005 -Bal Pharma wins best exporter award -The rights issue of Bal Pharma, Bangalore-based medium sized pharmaceutical company, has been oversubscribed 1.6 times. It has seen a fund generation of Rs 13.65 crore, as against the issue amount of Rs 11.75 crore. Bal Pharma issued 39.18 lakh equity shares of Rs 10 each to the existing shareholders on rights basis in the ratio of 3:5 at a price of Rs 30 per equity share, i.e. at a premium of Rs 20 per share amounting to Rs 11.75 crore. 2006 -The Company has obtained accreditation of Japanese Government as a foreign manufacturer for APIs and this shall certainly facilitate registration and marketing of the Company APIs in Japan. 2007 -The company has recommended a Dividend of Rs.7.5% per share. 2008 -Bal Pharma has recommended Dividend of 10% 2009 -Bal Pharma has recommended Dividend of Rs.0.75 per equity share of Rs.10 each. 2011 -Bal Pharma appointed Mr. D. Muarali as the Company Secretary & Compliance Officer of the company. 2012 -Bal Pharma appointed Mr. Venkatesan Murali as General Manager - Finance and Company Secretary of the Company. 2013 -Bal Pharma has recommended payment of dividend of Re. 0.75 (7.5%) per equity share of Rs. 10 each. 2014 -Bal Pharma has recommended payment of dividend of Re. 1/- (10%) per Equity Share of Rs. 10 each. 2015 -Bal Pharma Ltd has titled "Bal Pharma ventures into OTC Segment". 2021 -Bal Pharma Ltd has launched antiviral drug Favipiravir in the domestic market under the brand name BAL flu for the treatment of COVID-19. -Bal Pharma Limited has informed the Exchange about Acquisition of 650000 equity shares of the Company by Mr.Shailesh Siroya 2023 -NCLT given approval for merger of Golden Drugs Pvt Ltd with Bal Pharma Limited, 2024 -The Company commencement of the API green field project at Kadechur KIADB industrial Area, Yadgir District.